113 related articles for article (PubMed ID: 7103635)
1. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.
Brubaker LH; Brière J; Laszlo J; Kraut E; Landaw SA; Peterson P; Goldberg J; Donovan P
Arch Intern Med; 1982 Aug; 142(8):1533-7. PubMed ID: 7103635
[TBL] [Abstract][Full Text] [Related]
2. [Transfusion of recuperated blood in total knee arthroplasty].
Pitsaer E
Rev Chir Orthop Reparatrice Appar Mot; 2002 Dec; 88(8):777-89. PubMed ID: 12503019
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
7. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
[TBL] [Abstract][Full Text] [Related]
8. Danazol treatment of idiopathic myelofibrosis with severe anemia.
Cervantes F; Hernández-Boluda JC; Alvarez A; Nadal E; Montserrat E
Haematologica; 2000 Jun; 85(6):595-9. PubMed ID: 10870115
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
10. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.
Park SH; Nam E; Bang SM; Cho EK; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Jun; 62(1):1-9. PubMed ID: 17690882
[TBL] [Abstract][Full Text] [Related]
12. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
Glaspy JA; Charu V; Luo D; Moyo V; Kamin M; Wilhelm FE
Cancer; 2009 Mar; 115(5):1121-31. PubMed ID: 19170225
[TBL] [Abstract][Full Text] [Related]
13. A comparison of androgens for anemia in patients on hemodialysis.
Neff MS; Goldberg J; Slifkin RF; Eiser AR; Calamia V; Kaplan M; Baez A; Gupta S; Mattoo N
N Engl J Med; 1981 Apr; 304(15):871-5. PubMed ID: 7010161
[TBL] [Abstract][Full Text] [Related]
14. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
15. The myeloproliferative syndromes.
Linman JW
Hosp Pract (Off Ed); 1986 Apr; 21(4):116A-116CC. PubMed ID: 3082901
[No Abstract] [Full Text] [Related]
16. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
17. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
Lévy V; Bourgarit A; Delmer A; Legrand O; Baudard M; Rio B; Zittoun R
Am J Hematol; 1996 Dec; 53(4):239-41. PubMed ID: 8948661
[TBL] [Abstract][Full Text] [Related]
18. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery.
Kulier A; Levin J; Moser R; Rumpold-Seitlinger G; Tudor IC; Snyder-Ramos SA; Moehnle P; Mangano DT; ;
Circulation; 2007 Jul; 116(5):471-9. PubMed ID: 17620512
[TBL] [Abstract][Full Text] [Related]
19. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
[TBL] [Abstract][Full Text] [Related]
20. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
